Cargando…
P735: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES
Autores principales: | Robert Savona, Michael, K Mccloskey, James, A. Griffiths, Elizabeth, Yee, Karen, M. Zeidan, Amer, Al-Kali, Aref, Joachim Deeg, H., A. Patel, Prapti, Sabloff, Mitchell, Keating, Mary-Margaret, Y Zhu, Nancy, Gabrail, Nashat, Fazal, Salman, J. Maly, Joseph, Odenike, Olatoyosi, Kantarjian, Hagop, Dezern, Amy, L Oconnell, Casey, Roboz, Gail, Busque, Lambert, Buckstein, Rena, Amin, Harshad, K Randhawa, Jasleen, Leber, Brian, Dao, Kim-Hien, Chan, Winny, Oganesian, Aram, Sano, Yuri, Mirakhur, Beloo, Keer, Harold, Garcia-Manero, Guillermo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429272/ http://dx.doi.org/10.1097/01.HS9.0000969844.13426.20 |
Ejemplares similares
-
Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study
por: Savona, Michael R., et al.
Publicado: (2021) -
Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Savona, Michael R., et al.
Publicado: (2020) -
P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023) -
Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study
por: Garcia-Manero, Guillermo, et al.
Publicado: (2021) -
Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model
por: Ramsey, Haley E., et al.
Publicado: (2020)